Intralesional injections show promise for cutaneous melanoma (Provectus Pharmaceuticals Inc)

(Source: Provectus Pharmaceuticals Inc) 07 Oct 2014 by ecancer reporter Janet Fricker The poster session 'Melanoma and other skin tumours', held at ESMO 2014 in Madrid, highlighted the emerging field of intralesional injections for cutaneous melanoma leading to tumour regression not only in the injected lesions, but also in 'bystander' lesions suggesting that the strategy is augmenting immune response. Cutaneous melanoma represents a persistent morbidity, including disfigurement accompanied by pain, ulceration, bleeding and infection. Despite locoregional therapies, such as surgery and radiation, a significant percentage of patients have locally advanced disease at high risk for...